Efficacy of prescription-eligible digital health applications for depression and generalized anxiety disorder in Germany: a systematic review and meta-analysis.
A Schmitz, S Frey, A Karimzadeh et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of prescription-eligible digital health applications (DiGA) for depression and generalized anxiety disorder in Germany, analyzing 19 randomized controlled trials with 4,078 participants. The study found that these digital interventions significantly reduced symptom severity for depression, with a standardized mean difference (SMD) of -0.49 immediately post-intervention and -0.35 at follow-up.
Key findings
- Digital applications for depression showed a significant reduction in symptom severity with an SMD of -0.49 immediately after intervention.
- At follow-up, the reduction in depression symptoms remained significant with an SMD of -0.35.
- Evidence for generalized anxiety disorder was limited due to only two available studies.
Why it matters
The findings suggest that prescription-eligible digital health applications can be effective tools for managing depression, potentially enhancing treatment options in mental health care. Understanding their efficacy is crucial for integrating these technologies into clinical practice.
What to keep in mind
The evidence is dominated by a small number of applications, particularly Deprexis, which may not represent all available DiGAs.